Oorsprong van het eerstegraads netwerk van Omer Siddiqui
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 9 | |
Subsidiary | Biotechnology | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Omer Siddiqui via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Alta Partners Management Co. LP
Alta Partners Management Co. LP Investment ManagersFinance Alta Partners Management Co. LP (Alta Partners) is a venture capital firm founded in 1996 by Jean Deleage, Guy Paul Nohra, Marino Polestra and Garrett P. Gruener. The firm is headquartered in Jackson, Wyoming. | Investment Managers | Private Equity Investor Director/Board Member Private Equity Investor | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
ZS PHARMA INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Executive Officer Chief Tech/Sci/R&D Officer | |
The University of California, San Francisco | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
Stanford University School of Medicine | College/University | Doctorate Degree Corporate Officer/Principal | |
SARcode Bioscience, Inc.
SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Massachusetts Institute of Technology | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Harvard T.H. Chan School of Public Health | College/University | Graduate Degree Graduate Degree | |
EXELIXIS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Brown University | College/University | Undergraduate Degree Undergraduate Degree | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree | |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Director/Board Member | |
Neoprogen, Inc.
Neoprogen, Inc. BiotechnologyHealth Technology Neoprogen, Inc. engages in the development of cell-based therapy for people who experience a heart attack. The company was founded by Sunjay Kaushal, Rachana Mishra and Sudhish Sharma and is headquartered in Baltimore, MD. | Biotechnology | Director/Board Member | |
Rasmussen Biotech & Pharma Consulting LLC | Chief Executive Officer | ||
Novo-Nordisk Biochem, Inc. | Chief Tech/Sci/R&D Officer | ||
Nabi Pharmaceuticals | Chief Tech/Sci/R&D Officer | ||
GENVEC INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Renibus Therapeutics, Inc.
Renibus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Renibus Therapeutics, Inc. engages in manufacture of pharmaceutical products. The company was founded by Donald Jeffrey Keyser and Alvaro F. Guillem in 2015 and is headquartered in Southlake, TX. | Pharmaceuticals: Major | Founder | |
University of Copenhagen | College/University | Doctorate Degree | |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Analyst | |
Miami University | College/University | Undergraduate Degree | |
DIMENSION THERAPEUTICS INC | Biotechnology | Director/Board Member | |
Human Longevity, Inc.
Human Longevity, Inc. BiotechnologyHealth Technology Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
PERSONALIS, INC. | Medical/Nursing Services | Director/Board Member | |
Inventages II
Inventages II Investment ManagersFinance Inventages II invests in companies located in Bahamas. The fund focus on companies such as life science and consumer applications. It provides financing for seed, early and buyout capital requirements. | Investment Managers | Founder | |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Biotechnology | Director/Board Member | |
AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member | |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director/Board Member | |
ACELYRIN, INC. | Pharmaceuticals: Major | Director/Board Member | |
PRINCIPIA BIOPHARMA INC. | Pharmaceuticals: Major | Chairman | |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Teon Therapeutics, Inc.
Teon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Teon Therapeutics, Inc. operates as a pharmaceutical company. It focuses on cancer immunotherapy. The company was founded by Yao Lina, Fan Peidong, Elfaith Elzein, and Liiu Jiwen in March 2018 and is headquartered in Redwood City, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor | |
CELGENE | Biotechnology | Corporate Officer/Principal | |
Solve Therapeutics, Inc.
Solve Therapeutics, Inc. BiotechnologyHealth Technology Solve Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops novel antibody-based therapies targeting tumor-specific antigens. The company is based in Belmont, CA, and has subsidiaries in the United States. The company's formation has reunited members of the former VelosBio Inc. team, a highly experienced group with a proven ability to rapidly advance innovative therapeutics that address unmet medical needs in the treatment of cancer. Solvetx has been actively pursuing discovery and development efforts at its state-of-the-art laboratory facilities. The company has licensed or generated targeting antibodies and nanobodies with ideal characteristics to serve as the backbones for antibody-based therapeutics and has rights to technology supporting the development of diagnostic and therapeutic antibody-radionuclide conjugates (ARCs). Solvetx is supported by a syndicate of sophisticated healthcare investors, including Ayurmaya Capital Management Fund (an affiliate of Matrix Capital Management), Decheng Capital, General, and Surveyor Capital (a Citadel company). The company was founded by David M. Johnson and has been led by him as the CEO since incorporation. | Biotechnology | Director/Board Member | |
Anumana, Inc.
Anumana, Inc. Packaged SoftwareTechnology Services Anumana, Inc. is an AI-driven health technology company that leverages cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart. The company is based in Cambridge, MA, and has subsidiaries in the United States. Anumana's software-as-a-medical device (SAMd) solutions aim to detect hidden diseases using ECG-AI algorithms to enhance and improve care through real-time AI insights. The company was founded in 2021 by nference and Mayo Clinic to develop innovative AI technology applied to ECG, electrophysiology, and hemodynamics. The CEO is Murali Aravamudan. | Packaged Software | Director/Board Member | |
VERNALIS | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
The University of North Carolina at Asheville | College/University | Doctorate Degree | |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Medical Specialties | General Counsel | |
TL Ventures LP | Corporate Officer/Principal | ||
Columbia University College of Physicians & Surgeons | College/University | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 45 |
Zwitserland | 3 |
Frankrijk | 2 |
Denemarken | 2 |
Verenigd Koninkrijk | 2 |
Sectoraal
Health Technology | 26 |
Consumer Services | 10 |
Finance | 7 |
Health Services | 3 |
Commercial Services | 3 |
Operationeel
Director/Board Member | 94 |
Corporate Officer/Principal | 37 |
Chief Tech/Sci/R&D Officer | 25 |
Independent Dir/Board Member | 23 |
Chief Executive Officer | 14 |
Sterkste connecties
Insiders | |
---|---|
Daniel Janney | 47 |
Alan Colowick | 30 |
Steven James | 24 |
Henrik Rasmussen | 14 |
Gerald McMahon | 13 |
Robert Alexander | 13 |
Natalie Sacks | 13 |
Adam Tomasi | 10 |
Susan Jones | 9 |
Alejandro Dorenbaum | 9 |
Sally D. Bolmer | 8 |
Simon Greenwood | 6 |
Roland K. Winger | 5 |
- Beurs
- Insiders
- Omer Siddiqui
- Bedrijfsconnecties